English
|
Español
English
|
Español
Insurance
Marketing
Pharmaceuticals
Technology/Innovation
Regulatory
Community
U.S. House of Representatives
+
Regulatory
M. Y. Bailey
| Aug 7, 2026
PhRMA's Zirkelbach: 340B program has changed dramatically with 'little transparency into how patients benefit'
+
Regulatory
Nicholas Malfitano
| Jun 11, 2024
U.S. House Energy and Commerce on Oversight and Investigations Subcommittee Chair Griffith on 340B Program: 'it is not mandated to disclose where these dollars actually go and how much is made from the program'
+
Regulatory
Andy Nghiem
| Mar 15, 2022
New $1.5 trillion bill leaves out reimbursement for 'extremely valuable' home telehealth services
+
Regulatory
Michael McGrady
| Jun 15, 2017
Drug user fee reauthorization may spark innovation
+
Regulatory
John Breslin
| May 3, 2017
House poised to vote on amended health care bill
+
Community
John Breslin
| Apr 3, 2017
No move on Republican health care bill for months, expert predicts
+
Regulatory
John Breslin
| Mar 30, 2017
Low income, older people would have paid higher penalties under House health care bill
+
Regulatory
John Breslin
| Mar 27, 2017
Postal Service health care proposal could burden seniors, analyst says
Trending
+
Pharmaceuticals
Patient Daily
| Aug 4, 2026
Merck reports mixed results for tulisokibart in recent clinical trials and financial update
+
Pharmaceuticals
Patient Daily
| Aug 6, 2026
FDA approves Replimune’s melanoma drug Tudriqev after advisory committee debate
+
Regulatory
M. R. Armstrong
| Aug 4, 2026
Public Policy Solutions on 340B: 'The program has enriched big hospital execs'
+
Pharmaceuticals
Patient Daily
| Aug 5, 2026
Bristol Myers Squibb and AstraZeneca reportedly in merger talks amid industry changes
